olaparib

poly(ADP-ribose) polymerase 1 ; Homo sapiens







632 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34050611 Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy. 2022 Feb 2
2 34151456 Synthesis and evaluation of 2-(4-[4-acetylpiperazine-1-carbonyl] phenyl)-1H-benzo[d]imidazole-4-carboxamide derivatives as potential PARP-1 inhibitors and preliminary study on structure-activity relationship. 2022 Feb 1
3 34473525 Recent Advances in the Management of Metastatic Prostate Cancer. 2022 Jan 1
4 34629045 Treatment of Triple Negative Cell Lines with Olaparib to Block DNA Repair. 2022 1
5 34670865 GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress. 2022 Feb 1
6 34732853 Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. 2022 Jan 1
7 34812476 Metabolism‑related pharmacokinetic drug‑drug interactions with poly (ADP‑ribose) polymerase inhibitors (Review). 2022 Jan 2
8 34854226 Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors. 2022 Apr 1
9 34880123 cAMP-Mediated Autophagy Promotes Cell Survival via ROS-Induced Activation of PARP1: Implications for Treatment of Acute Lymphoblastic Leukemia. 2022 Mar 1 1
10 34954029 FDI-6 and olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. 2022 Jan 1
11 34969765 Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells. 2022 Jan 4
12 35000525 Repeated treatments of Capan-1 cells with PARP1 and Chk1 inhibitors promote drug resistance, migration and invasion. 2022 Dec 31 2
13 35091172 Design, synthesis and mechanism studies of novel dual PARP1/BRD4 inhibitors against pancreatic cancer. 2022 Feb 15 1
14 35097256 Positive Feedback Regulation of Poly(ADP-ribose) Polymerase 1 and the DNA-PK Catalytic Subunit Affects the Sensitivity of Nasopharyngeal Carcinoma to Etoposide. 2022 Jan 25 1
15 35130631 PARP-1 inhibitors enhance the chemosensitivity of leukemia cells by attenuating NF-кB pathway activity and DNA damage response induced by Idarubicin 2022 Jan 25 3
16 35156571 Durable Disease-Free Survival in a Patient with Metastatic Triple-Negative Breast Cancer Treated With Olaparib Monotherapy. 2022 Feb 14 2
17 35159068 Co-Inhibition of Androgen Receptor and PARP as a Novel Treatment Paradigm in Prostate Cancer-Where Are We Now? 2022 Feb 4 1
18 35163037 Sesquiterpene Lactones Potentiate Olaparib-Induced DNA Damage in p53 Wildtype Cancer Cells. 2022 Jan 20 2
19 35163134 THZ531 Induces a State of BRCAness in Multiple Myeloma Cells: Synthetic Lethality with Combination Treatment of THZ 531 with DNA Repair Inhibitors. 2022 Jan 21 1
20 35165509 Proguanil synergistically sensitizes ovarian cancer cells to olaparib by increasing DNA damage and inducing apoptosis. 2022 2
21 35188042 Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. 2022 Feb 20 2
22 35191009 Genetic medicine is accelerating in Japan. 2022 Feb 21 1
23 35194903 XRCC1 counteracts poly(ADP ribose)polymerase (PARP) poisons, olaparib and talazoparib, and a clinical alkylating agent, temozolomide, by promoting the removal of trapped PARP1 from broken DNA. 2022 May 4
24 35205643 Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. 2022 Feb 11 2
25 35267438 DNA Repair Enzyme Poly(ADP-Ribose) Polymerase 1/2 (PARP1/2)-Targeted Nuclear Imaging and Radiotherapy. 2022 Feb 23 1
26 35269669 Possible Action of Olaparib for Preventing Invasion of Oral Squamous Cell Carcinoma In Vitro and In Vivo. 2022 Feb 25 2
27 35324529 Rapid and durable response to fifth-line lorlatinib plus olaparib in an ALK-rearranged, BRCA2-mutated metastatic lung adenocarcinoma patient with critical tracheal stenosis: a case report. 2022 Mar 23 2
28 35343196 A review on mechanisms of resistance to PARP inhibitors. 2022 Mar 1
29 35400012 Complete Response of a Mutated BRCA2 Metastatic Clear Cell Endometrial Adenocarcinoma to the Poly (ADP ribose) Polymerase (PARP) Inhibitor Olaparib. 2022 Jan-Feb 3
30 35408930 Zafirlukast Induces VHL- and HIF-2α-Dependent Oxidative Cell Death in 786-O Clear Cell Renal Carcinoma Cells. 2022 Mar 25 1
31 35419627 An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. 2022 May 2
32 35444023 Olaparib-induced cutaneous side effects in a patient with recurrent ovarian cancer. 2022 Apr 20 1
33 35466317 Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. 2022 2
34 35480123 Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With ATM Mutation. 2022 1
35 35486574 Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin's lymphoma in vitro. 2022 3
36 35494030 Olaparib Combined With Dacomitinib in Osimertinib-Resistant Brain and Leptomeningeal Metastases From Non-Small Cell Lung Cancer: A Case Report and Systematic Review. 2022 2
37 35517402 Inducing Synergistic DNA Damage by TRIP13 and PARP1 Inhibitors Provides a Potential Treatment for Hepatocellular Carcinoma. 2022 2
38 35545049 The lactate-NAD+ axis activates cancer-associated fibroblasts by downregulating p62. 2022 May 10 2
39 35593736 First phase 1 clinical study of olaparib in pediatric patients with refractory solid tumors. 2022 May 20 1
40 35611209 Circulating tumor DNA genomic profiling reveals the complicated olaparib-resistance mechanism in prostate cancer salvage therapy: A case report. 2022 Apr 16 3
41 35619904 OGG1 Inhibition Triggers Synthetic Lethality and Enhances The Effect of PARP Inhibitor Olaparib in BRCA1-Deficient TNBC Cells. 2022 1
42 35624090 FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2'-deoxycytidine and 5-hydroxymethyl-2'-deoxyuridine. 2022 May 27 2
43 35628590 Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. 2022 May 21 1
44 35636395 Parp Inhibition and Beyond in Brca- Associated Breast Cancer in Women: A State- Of- The- Art Summary of (Pre) - Clinical Research into Risk Reduction and Clinical Benefits. 2022 May 30 1
45 32079692 Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma. 2021 Jan 1 1
46 32164505 A Review on Poly (ADP-ribose) Polymerase (PARP) Inhibitors and Synthetic Methodologies. 2021 1
47 32409690 TET1 promotes growth of T-cell acute lymphoblastic leukemia and can be antagonized via PARP inhibition. 2021 Feb 1
48 32790034 PARP Inhibitors and Prostate Cancer: To Infinity and Beyond BRCA. 2021 Jan 2
49 32814472 Inhibition of ELF3 confers synthetic lethality of PARP inhibitor in non-small cell lung cancer. 2021 Jun 1
50 33069804 Folliculin deficient renal cancer cells exhibit BRCA1 A complex expression impairment and sensitivity to PARP1 inhibitor olaparib. 2021 Feb 15 4